Psoriatic arthritis: Advances in pharmacotherapy based on molecular target

25Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

The progress on the improved understanding of disease pathogenesis and molecular biology has changed the understanding of disease profiles, emphasizing aspects that simple clinical observation could not identify, and demarcating differences between clinical pictures that seemed to overlap. An example of this spectacular evolution is represented by psoriatic arthritis (PsA). This increase of knowledge on pathogenesis has led to an important impact on therapeutic approach. Therapies are now taken into account because their precise target is known. The authors describe treatment guidelines and revisit traditional therapies as well as innovative therapies in PsA. © 2013 Informa UK, Ltd.

Cite

CITATION STYLE

APA

Scarpa, R., Costa, L., Atteno, M., Del Puente, A., Caso, F., & Moll, J. M. H. (2013, December). Psoriatic arthritis: Advances in pharmacotherapy based on molecular target. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2013.840292

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free